OTCPK:HLYK

Stock Analysis Report

Executive Summary

HealthLynked Corp. operates a cloud-based patient information network and record archiving system.

Snowflake

Fundamentals

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has HealthLynked's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.0%

HLYK

1.9%

US Healthcare Services

1.3%

US Market


1 Year Return

-41.3%

HLYK

13.1%

US Healthcare Services

5.9%

US Market

Return vs Industry: HLYK underperformed the US Healthcare Services industry which returned 13.1% over the past year.

Return vs Market: HLYK underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

HLYKIndustryMarket
7 Day8.0%1.9%1.3%
30 Day-13.8%-0.7%-1.9%
90 Day-28.9%-7.5%-1.8%
1 Year-41.3%-41.3%13.3%13.1%8.3%5.9%
3 Yearn/a56.9%56.4%45.6%36.2%
5 Yearn/a52.6%51.5%66.1%47.9%

Price Volatility Vs. Market

How volatile is HealthLynked's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is HealthLynked undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether HealthLynked is trading at an attractive price based on the cash flow it is expected to produce in the future. But as HealthLynked has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HLYK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through HealthLynked regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is HealthLynked forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HealthLynked has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of HLYK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access HealthLynked's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has HealthLynked performed over the past 5 years?

-51.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: HLYK is unprofitable, and losses have increased over the past 5 years at a rate of -51.5% per year.

Accelerating Growth: Unable to compare HLYK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HLYK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: HLYK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: HLYK is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: HLYK is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is HealthLynked's financial position?


Financial Position Analysis

Short Term Liabilities: HLYK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: HLYK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: HLYK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: HLYK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: HLYK has a high level of physical assets or inventory.

Debt Coverage by Assets: HLYK has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HLYK has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HLYK has less than a year of cash runway if free cash flow continues to reduce at historical rates of -42.8% each year


Next Steps

Dividend

What is HealthLynked's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate HLYK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HLYK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if HLYK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HLYK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HLYK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of HealthLynked's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Michael Dent (54yo)

2.8yrs

Tenure

US$65,846

Compensation

Dr. Michael T. Dent, M.D. serves as the Chief Executive Officer of HealthLynked Corp. since January 2017 and serves as its Chairman. Dr. Dent is the Co-Founder and Managing Partner of Inlight Capital Partn ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Michael's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.8yrs

Average Tenure

Experienced Management: HLYK's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

0.5yrs

Average Tenure

60yo

Average Age

Experienced Board: HLYK's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Michael Dent (54yo)

    Founder

    • Tenure: 2.8yrs
    • Compensation: US$65.85k
  • George O'Leary (56yo)

    CFO, COO & Director

    • Tenure: 0yrs
    • Compensation: US$567.33k
  • Richard Williamson

    Vice President of Marketing

    • Tenure: 0.5yrs

Board Members

  • Michael Dent (54yo)

    Founder

    • Tenure: 2.8yrs
    • Compensation: US$65.85k
  • Maher Albitar (64yo)

    Member of Scientific Advisory Board

    • Tenure: 0.9yrs
  • Bob Gasparini (64yo)

    Director

    • Tenure: 0.5yrs
  • George O'Leary (56yo)

    CFO, COO & Director

    • Tenure: 0yrs
    • Compensation: US$567.33k
  • Shawn Miller

    Member of Medical Advisory Board

    • Tenure: 0.08yrs

Company Information

HealthLynked Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: HealthLynked Corp.
  • Ticker: HLYK
  • Exchange: OTCPK
  • Founded: 2014
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$13.985m
  • Shares outstanding: 103.59m
  • Website: https://www.healthlynked.com

Number of Employees


Location

  • HealthLynked Corp.
  • 1726 Medical Boulevard
  • Suite 101
  • Naples
  • Florida
  • 34110
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HLYKOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 2017

Biography

HealthLynked Corp. operates a cloud-based patient information network and record archiving system. The company operates HealthLynked Network, which enables patients and doctors to keep track of medical inf ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:43
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.